NASDAQ (usa) arrow 6715.56 -12.11 -0.18%
FTSE 100 (london) arrow 7487.96 -5.12 -0.07%
DAX (german) arrow 13465.51 235.94 1.78%
NIKKEI 225 (japan) arrow 22420.08 408.47 1.86%
Hang - Seng (hong kong) arrow 28594.06 348.52 1.23%
NIFTY - 50 (india)
Straits Times (singapore) arrow 3391.61 17.53 0.52%
KOSPI (korea) arrow 2556.47 33.04 1.31%
All Ordinaries (australia) arrow 6005.30 28.90 0.48%
BOVESPA (brazil) arrow 74092.76 -215.73 -0.29%

Imugene Limited (PINK: IUGNF)

 
IUGNF Technical Analysis
5
As on 25th Dec 2024 IUGNF STOCK Price closed @ 0.02 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 0.06 & Strong Sell for SHORT-TERM with Stoploss of 0.07 we also expect STOCK to react on Following IMPORTANT LEVELS.
 
 

IUGNFSTOCK Price

Open 0.03 Change Price %
High 0.03 1 Day -0.01 -33.33
Low 0.02 1 Week -0.01 -33.33
Close 0.02 1 Month -0.01 -33.33
Volume 10000 1 Year -0.06 -75.00
52 Week High 0.09 | 52 Week Low 0.03
 
PINK USA Most Active Stocks
TXGE 3316.21 2.69%
TMSH 0.00 %
GTVH 0.00 %
TWOH 0.00 %
APLD 5.30 1.73%
RDAR 0.00 %
RSHN 0.00 %
AFFU 0.00 %
BFCH 0.00 %
WRFX 0.01 %
 
PINK USA Top Gainers Stocks
ANAV 12.05 30025.00%
PRKA 38.00 9400.00%
CGGYY 41.88 6765.57%
BKGM 950.00 6566.67%
SNPW 1.00 4900.00%
GPGC 0.40 3900.00%
WRRZF 0.21 950.00%
NZERD 0.36 800.00%
LOGQ 0.49 716.67%
MEIL 0.08 700.00%
 
PINK USA Top Losers Stocks
SYGGF 0.00 -100.00%
SUIC 0.00 -100.00%
SKLV 0.06 -100.00%
SKLV 0.06 -100.00%
DKLRF 0.85 -100.00%
DKLRF 0.85 -100.00%
TLDE 0.00 -100.00%
XTXXF 0.01 -95.45%
WFCNP 0.05 -95.45%
FFVWF 0.01 -94.12%
 
 
IUGNF
Daily Charts
IUGNF
Intraday Charts
Whats New @
Bazaartrend
IUGNF
Free Analysis
 
IUGNF Important Levels Intraday
RESISTANCE0.04
RESISTANCE0.03
RESISTANCE0.03
RESISTANCE0.03
SUPPORT0.01
SUPPORT0.01
SUPPORT0.01
SUPPORT0.00
 
IUGNF Forecast May 2025
4th UP Forecast0.06
3rd UP Forecast0.05
2nd UP Forecast0.04
1st UP Forecast0.03
1st DOWN Forecast0.01
2nd DOWN Forecast0
3rd DOWN Forecast-0.01
4th DOWN Forecast-0.02
 
IUGNF Weekly Forecast
4th UP Forecast0.06
3rd UP Forecast0.05
2nd UP Forecast0.04
1st UP Forecast0.03
1st DOWN Forecast0.01
2nd DOWN Forecast0.00
3rd DOWN Forecast-0.01
4th DOWN Forecast-0.02
 
IUGNF Forecast2025
4th UP Forecast0.17
3rd UP Forecast0.12
2nd UP Forecast0.09
1st UP Forecast0.06
1st DOWN Forecast-0.02
2nd DOWN Forecast-0.05
3rd DOWN Forecast-0.08
4th DOWN Forecast-0.13
 
 
IUGNF Other Details
Segment EQ
Market Capital 2049204096.00
Sector Healthcare
Industry Biotechnology
Offical website >
 
IUGNF Address
IUGNF
 
IUGNF Latest News
 
Your Comments and Response on Imugene Limited
 
IUGNF Business Profile
Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumors in Australia. Its lead product is HER-Vaxx, a HER2-positive cancer vaccine that stimulates a polyclonal antibody response against HER2/neu receptors in gastric and breast cancer. The company's HER-Vaxx is in Phase 1b/2 study for gastric cancer. It also engages in developing PD1-Vaxx, a cancer vaccine that aims to induce the body to produce polyclonal antibodies that block PD-1 signalling; B-Vaxx, a cancer vaccine to treat tumors that over-express the HER2/neu receptor; and CF33, a combination of genomic sequences from various vaccinia virus strains to generate potent virus. The company has a research collaboration with Celularity Inc. to develop the combination of Imugene's CD19 oncolytic virus technology and Celularity's CD19 targeting allogeneic chimeric antigen receptor T-cell therapy, CyCART-19 for the treatment of solid tumors. Imugene Limited was incorporated in 1986 and is based in Sydney, Australia. Address: 37 Bligh Street, Sydney, NSW, Australia, 2000
 
© 2005-2023 BazaarTrend.com All rights reserved.

Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service